Suppr超能文献

快速、基于结构的哌啶酸酰胺类 FK506 结合蛋白 51 新型选择性拮抗剂的探索

Rapid, Structure-Based Exploration of Pipecolic Acid Amides as Novel Selective Antagonists of the FK506-Binding Protein 51.

机构信息

Department of Translational Research in Psychiatry, Max Planck Institute of Psychiatry , Kraepelinstrasse 2, 80804 Munich, Germany.

Department of Cellular Biochemistry, Max Planck Institute of Biochemistry , Am Klopferspitz 18, 82152 Martinsried, Germany.

出版信息

J Med Chem. 2016 Mar 24;59(6):2410-22. doi: 10.1021/acs.jmedchem.5b01355. Epub 2016 Mar 8.

Abstract

The FK506-binding protein 51 (FKBP51) is a key regulator of stress hormone receptors and an established risk factor for stress-related disorders. Drug development for FKBP51 has been impaired by the structurally similar but functionally opposing homologue FKBP52. High selectivity between FKBP51 and FKBP52 can be achieved by ligands that stabilize a recently discovered FKBP51-favoring conformation. However, drug-like parameters for these ligands remained unfavorable. In the present study, we replaced the potentially labile pipecolic ester group of previous FKBP51 ligands by various low molecular weight amides. This resulted in the first series of pipecolic acid amides, which had much lower molecular weights without affecting FKBP51 selectivity. We discovered a geminally substituted cyclopentyl amide as a preferred FKBP51-binding motif and elucidated its binding mode to provide a new lead structure for future drug optimization.

摘要

FK506 结合蛋白 51(FKBP51)是应激激素受体的关键调节剂,也是与应激相关障碍相关的既定风险因素。FKBP51 的药物开发受到结构相似但功能相反的同源物 FKBP52 的阻碍。通过稳定最近发现的 FKBP51 有利构象的配体,可以在 FKBP51 和 FKBP52 之间实现高选择性。然而,这些配体的药物样参数仍然不理想。在本研究中,我们用各种低分子量酰胺替代了先前 FKBP51 配体中潜在不稳定的哌啶酸酯基。这导致了第一个哌啶酸酰胺系列,其分子量低得多,而不影响 FKBP51 的选择性。我们发现双取代的环戊基酰胺是 FKBP51 的首选结合基序,并阐明了其结合模式,为未来的药物优化提供了新的先导结构。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验